Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Exclusion Criteria

• •1. Any of the following laboratory abnormalities
• •1. Absolute neutrophil count (ANC) \<1,500 cells/mm\^3 (1.5 x 10\^9/L)
• •2. Platelet count \<100,000/mm\^3 (100 x 10\^9/L)
• •3. Serum creatinine \>2.5 mg/dL (221 mmol/L)
• •4. Serum Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamic-pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) \>5.0 x upper limit of normal (ULN)
• •5. Serum total bilirubin \>2.0 mg/dL (34 mmol/L)
• •2. Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• •3. All participants with Central Nervous System (CNS) disease with the exception of those subjects whose CNS disease has been treated with chemotherapy, radiotherapy or surgery and remains asymptomatic, with no active CNS disease, as shown by lumbar puncture, computerized tomography (CT) scan or Magnetic resonance imaging (MRI), for at least 6 months.
• •4. Prior history of malignancies other than non-Hodgkin's lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the participant has been free of the disease for \> or equal to 1 year.
• •5. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from signing the informed consent form.
• •6. Known positive for human immunodeficiency virus (HIV).
• •7. Pregnant or lactating females.
• •8. Prior \> or equal to grade 3 allergic reaction/hypersensitivity to thalidomide.
• •9. Prior \> or equal to grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
• •10. Prior use of lenalidomide.
• •11. Use of any standard or experimental anti-cancer drug therapy within 28 days of day 1 of study drug therapy.
• •12. Known active Hepatitis C.